贝伐单抗结合培美曲塞铂类对肺腺癌晚期的疗效研究  

Efficacy of Bevacizumab and Pemetrexed Platinum for Advanced Lung Adenocarcinoma

作　　者：郑丽平 邓海燕 刘丹 ZHENG Liping;DENG Haiyan;LIU Dan(Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing,100039)

机构地区：[1]北京中西医结合医院,100039

出　　处：《实用癌症杂志》2018年第7期1161-1164,共4页The Practical Journal of Cancer

摘　　要：目的研究贝伐单抗结合培美曲塞加铂类对肺腺癌的疗效。方法选取肺腺癌的66例患者,随机分为试验组33例、对照组33例,试验组患者使用贝伐单抗结合培美曲塞铂类治疗,对照组使用美曲塞加铂类治疗,18天为1个周期,两组患者均治疗4个周期。结果试验组4例,对照组5例因肿瘤进展在化疗4-6个周期而停止治疗,其余均完成了6个周期的治疗。试验组有效例数29例,CR 0例、PR 16例、SD 8例、PD 5例;对照组有效例数28例,CR 0例、PR12例、SD 5例、PD 11例。试验组ORR为55.17%(16/29),DCR为82.76%(24/29);对照组ORR为42.86%(12/28),DCR为60.71%(17/28);两组DCR分别为58.7%和28.3%,DCR分别为84.6%和28.4%。试验组有效率比对照组高,差异有统计学意义(P<0.05)。试验组的疾病发展时间为8.5个月(95%CI:7.5~9.3个月),中位OS14.5个月(95%CI:11.8~17.6个月);对照组分别为6.2个月(95%CI:5.6~6.9个月)和11.5个月(95%CI:9.3~13.6个月),均显著延长,两组对比差异有统计学意义(P<0.05)。结论贝伐单抗结合培美曲塞铂类对治疗肺腺癌晚期的患者无论近期还是远期疗效显著。Objective To study the curative effect of bevacizumab combined with pemetrexed plus platinum for lung adenocarcinoma. Methods 66 patients with lung adenocarcinoma were randomly divided into the experimental group （ n =33） and the control group（ n =33）.Patients in the experimental group were treated with bevacizumab combined with pemetrexed platinum,while the control group were treated with methotrexate plus platinum Treatment,18 days for a cycle,two groups of patients were treated for 4 cycles. Results 4 patients in the experimental group and 5 patients in the control group were treated for 4-6 cycles of chemotherapy due to tumor progression,and the remaining 6 cycles were completed.The number of effective cases in the trial group was 28 cases,CR 0 cases,PR 16 cases,SD 8 cases,PD 5 cases;control group 28 cases,CR 0 cases,PR 12 cases,SD 5 cases,PD 11 cases.ORR of the experimental group（16/29）55.17%,DCR（24/29）82.76%; ORR of the control group（12/28）42.86%,DCR（17/28）60.71%;of ehe 2 groups DCR were 58.7% and 28.3%,respectively,DCR were 84.6% and 28.4%.The experimental group was more effective than the control group,and the difference was statistically significant （ P 〈0.05）.The disease progression time of the experimental group was 8.5 months （95%CI： 7.5 to 9.3 months）,the median OS was 14.5 months （95%CI： 11.8 to 17.6 months）,and the control group was 6.2 months （95%CI：5.6 to 6.9 months and 11.5 months （95%CI：9.3 to 13.6 months）,all significantly prolonged.There was a statistically significant difference between the 2 groups （ P 〈0.05）. Conclusion Bevacizumab combined with pemetrexed platinum is effective in the treatment of patients with advanced stage lung adenocarcinoma both in the short and long term.

关 键 词：贝伐单抗 肺腺癌晚期 生存率 

分 类 号：R734.2[医药卫生—肿瘤]